

# Myotonic Dystrophy Drug-United States Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/M141DBB49C6MEN.html

Date: May 2018

Pages: 139

Price: US\$ 3,480.00 (Single User License)

ID: M141DBB49C6MEN

#### **Abstracts**

#### **Report Summary**

Myotonic Dystrophy Drug-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Myotonic Dystrophy Drug industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Myotonic Dystrophy Drug 2013-2017, and development forecast 2018-2023

Main market players of Myotonic Dystrophy Drug in United States, with company and product introduction, position in the Myotonic Dystrophy Drug market Market status and development trend of Myotonic Dystrophy Drug by types and applications

Cost and profit status of Myotonic Dystrophy Drug, and marketing status Market growth drivers and challenges

The report segments the United States Myotonic Dystrophy Drug market as:

United States Myotonic Dystrophy Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England
The Middle Atlantic
The Midwest
The West



The South

Southwest

United States Myotonic Dystrophy Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

ISIS-DMPKRx

PRO-135

SRT-152

VAL-0411

Others

United States Myotonic Dystrophy Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Clinic

Home Use

Others

United States Myotonic Dystrophy Drug Market: Players Segment Analysis (Company and Product introduction, Myotonic Dystrophy Drug Sales Volume, Revenue, Price and Gross Margin):

BioMarin Pharmaceutical Inc.

F. Hoffmann-La Roche Ltd.

Genzyme Corporation

Isis Pharmaceuticals, Inc.

Marina Biotech, Inc.

Valentia Biopharma S.L.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



#### **Contents**

#### CHAPTER 1 OVERVIEW OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)

- 1.1 Definition of Active Pharmaceutical Ingredients (API) in This Report
- 1.2 Commercial Types of Active Pharmaceutical Ingredients (API)
  - 1.2.1 Vitamin
  - 1.2.2 Antibiotics
  - 1.2.3 Antipyretic & Analgesic
  - 1.2.4 Hormone
  - 1.2.5 Amino Acid
  - 1.2.6 Nervus Centralis
- 1.2.7 Others
- 1.3 Downstream Application of Active Pharmaceutical Ingredients (API)
  - 1.3.1 Hospital
- 1.3.2 Clinic
- 1.3.3 Others
- 1.4 Development History of Active Pharmaceutical Ingredients (API)
- 1.5 Market Status and Trend of Active Pharmaceutical Ingredients (API) 2013-2023
- 1.5.1 Global Active Pharmaceutical Ingredients (API) Market Status and Trend 2013-2023
- 1.5.2 Regional Active Pharmaceutical Ingredients (API) Market Status and Trend 2013-2023

#### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Active Pharmaceutical Ingredients (API) 2013-2017
- 2.2 Production Market of Active Pharmaceutical Ingredients (API) by Regions
  - 2.2.1 Production Volume of Active Pharmaceutical Ingredients (API) by Regions
  - 2.2.2 Production Value of Active Pharmaceutical Ingredients (API) by Regions
- 2.3 Demand Market of Active Pharmaceutical Ingredients (API) by Regions
- 2.4 Production and Demand Status of Active Pharmaceutical Ingredients (API) by Regions
- 2.4.1 Production and Demand Status of Active Pharmaceutical Ingredients (API) by Regions 2013-2017
- 2.4.2 Import and Export Status of Active Pharmaceutical Ingredients (API) by Regions 2013-2017

#### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**



- 3.1 Production Volume of Active Pharmaceutical Ingredients (API) by Types
- 3.2 Production Value of Active Pharmaceutical Ingredients (API) by Types
- 3.3 Market Forecast of Active Pharmaceutical Ingredients (API) by Types

### CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Active Pharmaceutical Ingredients (API) by Downstream Industry
- 4.2 Market Forecast of Active Pharmaceutical Ingredients (API) by Downstream Industry

# CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)

- 5.1 Global Economy Situation and Trend Overview
- 5.2 Active Pharmaceutical Ingredients (API) Downstream Industry Situation and Trend Overview

### CHAPTER 6 ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 6.1 Production Volume of Active Pharmaceutical Ingredients (API) by Major Manufacturers
- 6.2 Production Value of Active Pharmaceutical Ingredients (API) by Major Manufacturers
- 6.3 Basic Information of Active Pharmaceutical Ingredients (API) by Major Manufacturers
- 6.3.1 Headquarters Location and Established Time of Active Pharmaceutical Ingredients (API) Major Manufacturer
- 6.3.2 Employees and Revenue Level of Active Pharmaceutical Ingredients (API) Major Manufacturer
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

#### CHAPTER 7 ACTIVE PHARMACEUTICAL INGREDIENTS (API) MAJOR



#### MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Teva Active Pharmaceutical Industries Limited
  - 7.1.1 Company profile
  - 7.1.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.1.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Teva Active Pharmaceutical Industries Limited
- 7.2 DSM
  - 7.2.1 Company profile
  - 7.2.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.2.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of DSM
- 7.3 Novartis
  - 7.3.1 Company profile
  - 7.3.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.3.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Novartis
- 7.4 Roche
  - 7.4.1 Company profile
  - 7.4.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.4.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Roche
- 7.5 Johnson & Johnson
  - 7.5.1 Company profile
  - 7.5.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.5.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.6 Dr. Reddy's
  - 7.6.1 Company profile
  - 7.6.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.6.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Dr. Reddy's
- 7.7 Pfizer
  - 7.7.1 Company profile
  - 7.7.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.7.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Pfizer
- 7.8 Bayer
  - 7.8.1 Company profile



- 7.8.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.8.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Bayer
- **7.9 BASF** 
  - 7.9.1 Company profile
  - 7.9.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.9.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of BASF
- 7.10 Cambrex
  - 7.10.1 Company profile
  - 7.10.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.10.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Cambrex
- 7.11 Sun Pharmaceutical Industries
  - 7.11.1 Company profile
  - 7.11.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.11.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Sun Pharmaceutical Industries
- 7.12 Lonza group
  - 7.12.1 Company profile
  - 7.12.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.12.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Lonza group
- 7.13 Boehringer Ingelheim GmbH
  - 7.13.1 Company profile
  - 7.13.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.13.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH
- 7.14 Aurobindo pharma
  - 7.14.1 Company profile
  - 7.14.2 Representative Active Pharmaceutical Ingredients (API) Product
- 7.14.3 Active Pharmaceutical Ingredients (API) Sales, Revenue, Price and Gross Margin of Aurobindo pharma

# CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)

- 8.1 Industry Chain of Active Pharmaceutical Ingredients (API)
- 8.2 Upstream Market and Representative Companies Analysis



#### 8.3 Downstream Market and Representative Companies Analysis

# CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)

- 9.1 Cost Structure Analysis of Active Pharmaceutical Ingredients (API)
- 9.2 Raw Materials Cost Analysis of Active Pharmaceutical Ingredients (API)
- 9.3 Labor Cost Analysis of Active Pharmaceutical Ingredients (API)
- 9.4 Manufacturing Expenses Analysis of Active Pharmaceutical Ingredients (API)

### CHAPTER 10 MARKETING STATUS ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

#### **CHAPTER 11 REPORT CONCLUSION**

#### **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference



#### I would like to order

Product name: Myotonic Dystrophy Drug-United States Market Status and Trend Report 2013-2023

Product link: <a href="https://marketpublishers.com/r/M141DBB49C6MEN.html">https://marketpublishers.com/r/M141DBB49C6MEN.html</a>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

#### **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/M141DBB49C6MEN.html">https://marketpublishers.com/r/M141DBB49C6MEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970